CN103571872B - 一种能够表达人抗体的转基因动物的制备方法 - Google Patents
一种能够表达人抗体的转基因动物的制备方法 Download PDFInfo
- Publication number
- CN103571872B CN103571872B CN201210281415.1A CN201210281415A CN103571872B CN 103571872 B CN103571872 B CN 103571872B CN 201210281415 A CN201210281415 A CN 201210281415A CN 103571872 B CN103571872 B CN 103571872B
- Authority
- CN
- China
- Prior art keywords
- gene
- people
- light chain
- locus
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 241001465754 Metazoa Species 0.000 title description 56
- 230000009261 transgenic effect Effects 0.000 title description 42
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 128
- 239000012634 fragment Substances 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 46
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 31
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 31
- 241000699670 Mus sp. Species 0.000 claims abstract description 24
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 20
- 241000699660 Mus musculus Species 0.000 claims abstract description 15
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 230000008707 rearrangement Effects 0.000 claims abstract description 10
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 32
- 210000000349 chromosome Anatomy 0.000 claims description 8
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 7
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 26
- 108700019146 Transgenes Proteins 0.000 description 26
- 210000003719 b-lymphocyte Anatomy 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 14
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 210000004602 germ cell Anatomy 0.000 description 10
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000012239 gene modification Methods 0.000 description 7
- 230000005017 genetic modification Effects 0.000 description 7
- 235000013617 genetically modified food Nutrition 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000000520 microinjection Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000008676 import Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229940097572 chloromycetin Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000027326 copulation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150052384 50 gene Proteins 0.000 description 1
- 241000585705 Alicia <angiosperm> Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101100111164 Arabidopsis thaliana BAC2 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001214789 Basilea Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241001416149 Ovis ammon Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210281415.1A CN103571872B (zh) | 2012-08-09 | 2012-08-09 | 一种能够表达人抗体的转基因动物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210281415.1A CN103571872B (zh) | 2012-08-09 | 2012-08-09 | 一种能够表达人抗体的转基因动物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103571872A CN103571872A (zh) | 2014-02-12 |
CN103571872B true CN103571872B (zh) | 2016-11-23 |
Family
ID=50044583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210281415.1A Active CN103571872B (zh) | 2012-08-09 | 2012-08-09 | 一种能够表达人抗体的转基因动物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103571872B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105441455B (zh) * | 2015-10-21 | 2020-08-28 | 重庆金迈博生物科技有限公司 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
CN105777894A (zh) * | 2016-03-12 | 2016-07-20 | 长春力太生物技术有限公司 | 通过转基因啮齿类动物制备人源化驼类单域抗体的方法 |
CN109280674B (zh) * | 2017-07-21 | 2020-12-01 | 北京百奥赛图基因生物技术有限公司 | 一种筛选抗体的非人模式动物的构建方法及其应用 |
CN117099741A (zh) * | 2019-02-18 | 2023-11-24 | 百奥赛图(北京)医药科技股份有限公司 | 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物 |
KR20220006085A (ko) | 2019-05-30 | 2022-01-14 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | 클라우딘(Claudin) 18.2를 표적화하는 항체 또는 키메라 항원 수용체 |
KR20220007120A (ko) | 2019-06-10 | 2022-01-18 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | 항-cd25 항체 및 이의 적용 |
AU2020290119A1 (en) | 2019-06-10 | 2021-10-07 | Shandong Boan Biotechnology Co., Ltd. | Bifunctional fusion protein against PDL1 and TGFβ and use thereof |
WO2021244522A1 (en) | 2020-06-02 | 2021-12-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
JP2023541216A (ja) * | 2020-06-25 | 2023-09-29 | ヒューマブ カンパニー リミテッド | ヘテロ接合型トランスジェニック動物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002549A (zh) * | 1995-10-10 | 2007-07-25 | 真药物国际公司 | 能够生产异源抗体的转基因非人动物 |
EP2294917A1 (en) * | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
CN102123582A (zh) * | 2008-06-27 | 2011-07-13 | 莫鲁斯有限公司 | 产生抗体的非人哺乳动物 |
CN102292445A (zh) * | 2008-12-18 | 2011-12-21 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
-
2012
- 2012-08-09 CN CN201210281415.1A patent/CN103571872B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002549A (zh) * | 1995-10-10 | 2007-07-25 | 真药物国际公司 | 能够生产异源抗体的转基因非人动物 |
EP2294917A1 (en) * | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
CN102123582A (zh) * | 2008-06-27 | 2011-07-13 | 莫鲁斯有限公司 | 产生抗体的非人哺乳动物 |
CN102292445A (zh) * | 2008-12-18 | 2011-12-21 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
Non-Patent Citations (4)
Title |
---|
Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and k loci and expression of fully human antibodies;Kazuma Tomizuka et.al.,;《PNAS》;20000118;第97卷(第2期);第722页左栏第1段,第723页左栏第5段 * |
Kymab: More mAb diversity;Stephen Hansen;《biocentury》;20120227;第2页第3段 * |
Next Generation In Vivo Human Antibody Platform;KYMOUSE;《Non confidential partnering presentation》;20111031;第1-17页 * |
人源化抗体研究历程及发展趋势;林芸等;《生物工程学报》;20040131;第20卷(第1期);第1-5页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103571872A (zh) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103571872B (zh) | 一种能够表达人抗体的转基因动物的制备方法 | |
US11230697B2 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
JP3523245B1 (ja) | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 | |
JP6073550B2 (ja) | 遺伝子操作した動物から得られるヒトポリクローナル抗体 | |
WO2022166802A1 (zh) | 抗人cd271的单克隆抗体及用途 | |
US20170218336A1 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
US20210017253A1 (en) | Nucleic acid molecules and applications thereof in preparing human single-domain antibody | |
CN101595128A (zh) | 免疫应答增强的转基因动物和用于制备其的方法 | |
WO2001019394A2 (en) | Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds | |
CN105777894A (zh) | 通过转基因啮齿类动物制备人源化驼类单域抗体的方法 | |
WO2017067043A1 (zh) | 一种嵌合核酸分子及其在人源化抗体制备中的应用 | |
Mompó et al. | Antigen-specific human monoclonal antibodies from transgenic mice | |
Mompó et al. | Antigen-specific human monoclonal antibodies from transgenic mice | |
US20130291134A1 (en) | Humanized transgenic mouse model | |
CN102333874A (zh) | 具有增强的免疫球蛋白重链类别转换至Cε的高IgE动物模型 | |
CN106715700A (zh) | 能产生比小鼠IgE量高出许多的人源化IgE的基因转殖动物 | |
Lim et al. | Production of anti-phosphorylcholine antibodies of the T15 idiotype in CBA/N xid mice: investigation of the defect using a T15 immunoglobulin transgene | |
US20210009670A1 (en) | Nucleic acid molecules and applications thereof in human antibody | |
TR202021671A2 (tr) | Covid-19 salginina karşi kullanilmak üzere bi̇r aşi üreti̇m yöntemi̇ | |
EP1604997A1 (en) | Human polyclonal antibodies from transgenic nonhuman animals | |
JPH0335798A (ja) | 抗hlaモノクローナル抗体の製造方法 | |
CN101886082A (zh) | 利用动物乳腺生物反应器生产人源化单克隆抗体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LVYE INVESTMENT GROUP CO., LTD. Effective date: 20140731 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140731 Address after: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant after: Shandong International Biotechnology Park Development Co., Ltd. Applicant after: Lvye Investment Group Co., Ltd. Address before: 264670 high tech Zone, Shandong, Yantai science and technology Avenue, No. 39 Applicant before: Shandong International Biotechnology Park Development Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB02 | Change of applicant information |
Inventor after: Feng Dongxiao Inventor after: Xu Dongxue Inventor after: Gao Yan Inventor after: Li Bing Inventor after: Zhang Shumin Inventor after: Yang Xiaoping Inventor after: Dai Jie Inventor after: Zhang Hui Inventor after: Xu Conglun Inventor after: Dong Chuangchuang Inventor after: Liu Hong Inventor after: Zhao Ming Inventor before: Feng Dongxiao Inventor before: Dai Jie Inventor before: Zhang Hui Inventor before: Xu Conglun Inventor before: Dong Chuangchuang Inventor before: Liu Hong |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190930 Address after: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Co-patentee after: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY CO., LTD. Patentee after: Shandong International Biotechnology Park Development Co., Ltd. Address before: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Co-patentee before: Lvye Investment Group Co., Ltd. Patentee before: Shandong International Biotechnology Park Development Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201027 Address after: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Patentee after: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Patentee before: SHANDONG INTERNATIONAL BIOTECHNOLOGY PARK DEVELOPMENT Co.,Ltd. Patentee before: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264670 No. 39 Science and Technology Avenue, Yantai High-tech Zone, Shandong Province Patentee after: Shandong Boan Biotechnology Co.,Ltd. Address before: 264670 No. 39 Science and Technology Avenue, Yantai High-tech Zone, Shandong Province Patentee before: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. |